What Is the Status of Diabetes
Research? NIDDK conducts research in its
own laboratories and supports a great deal
of basic and clinical research in medical
centers and hospitals throughout the
United States. It also gathers and
analyzes statistics about diabetes. Other
Institutes at the National Institutes of
Health (NIH) conduct and support research
on diabetes-related eye diseases, heart
and vascular complications, pregnancy, and
dental problems.
Other Government agencies that sponsor
diabetes programs are the Centers for
Disease Control and Prevention, the Indian
Health Service, the Health Resources and
Services Administration, the Department of
Veterans Affairs, and the Department of
Defense.
Many organizations outside of the
Government support diabetes research and
education activities. These organizations
include the American Diabetes Association,
the Juvenile Diabetes Research Foundation
International, and the American
Association of Diabetes Educators.
In recent years, advances in diabetes
research have led to better ways to manage
diabetes and treat its complications.
Major advances include
• The development of a quick-acting
insulin analog.
• Better ways to monitor blood glucose and
for people with diabetes to check their
own blood glucose levels.
• Development of external insulin pumps
that deliver insulin, replacing daily
injections.
• Laser treatment for diabetic eye
disease, reducing the risk of blindness.
• Successful transplantation of kidneys
and pancreas in people whose own kidneys
fail because of diabetes.
• Better ways of managing diabetes in
pregnant women, improving chances of
successful outcomes.
• New drugs to treat type 2 diabetes and
better ways to manage this form of
diabetes through weight control.
• Evidence that intensive management of
blood glucose reduces and may prevent
development of diabetes complications.
• Demonstration that antihypertensive
drugs called ACE (angiotensin-converting
enzyme) inhibitors prevent or delay kidney
failure in people with diabetes.
• Promising results with islet
transplantation for type 1 diabetes
reported by the University of Alberta in
Canada. A nationwide clinical trial funded
by the NIH and the Juvenile Diabetes
Research Foundation International is
currently trying to replicate the Canadian
advance.
• Evidence that people at high risk for
type 2 diabetes can lower their chances of
developing the disease through diet and
exercise.
What Will the Future Bring? In the future,
it may be possible to administer insulin
through inhalers, a pill, or a patch.
Devices are also being developed that can
monitor blood glucose levels without
having to prick a finger to get a blood
sample.
Researchers continue to search for the
cause or causes of diabetes and ways to
prevent and cure the disorder. Scientists
are looking for genes that may be involved
in type 1 or type 2 diabetes. Some genetic
markers for type 1 diabetes have been
identified, and it is now possible to
screen relatives of people with type 1
diabetes to see if they are at risk.
The Diabetes Prevention Trial--Type 1
(DPT-1) identifies relatives at risk for
developing type 1 diabetes and treats them
with an oral form of insulin in the hope
of preventing type 1 diabetes. In the same
study, researchers recently completed a
separate trial in which they found that
low-dose insulin injections do not prevent
type 1 diabetes in relatives of people
with type 1 diabetes. For more
information, call 1-800-HALT-DM1
(1-800-425-8361) or see
www.niddk.nih.gov/patient/
dpt_1/dpt_1.htm on the Internet.
The DPT-1 is funded by the NIDDK, the
National Institute of Allergy and
Infectious Diseases, the National
Institute of Child Health and Human
Development, and the National Center for
Research Resources within the National
Institutes of Health as well as the
American Diabetes Association and the
Juvenile Diabetes Research Foundation
International.
Transplantation of the pancreas or
insulin-producing beta cells offers the
best hope of cure for people with type 1
diabetes. Some pancreas transplants have
been successful. However, people who have
transplants must take powerful drugs to
prevent rejection of the transplanted
organ. These drugs are costly and may
eventually cause other health problems.
Scientists are working to develop less
harmful drugs and better methods of
transplanting beta cells to prevent
rejection by the body. Using techniques of
bioengineering, researchers are also
trying to create artificial beta cells
that secrete insulin in response to
increased glucose levels in the blood.
Recently, researchers at the University of
Alberta in Edmonton, Canada, announced
promising results with islet
transplantation in seven patients with
type 1 diabetes. At the time of the report
in the New England Journal of Medicine,
all seven patients who had received the
transplant remained free of insulin
injections up to 14 months after the
procedure.
A clinical trial funded by the NIH and the
Juvenile Diabetes Research Foundation
International will try to replicate the
Edmonton advance. With the insights gained
from this trial and other studies,
scientists hope to further refine methods
of islet harvesting and transplantation
and learn more about the immune processes
that affect rejection and acceptance of
transplanted islets.
In 1996, NIDDK launched its Diabetes
Prevention Program (DPP). The goal of this
research effort was to learn how to
prevent or delay type 2 diabetes in people
with impaired glucose tolerance (IGT), a
strong risk factor for type 2 diabetes.
The findings of the DPP, which were
released in August 2001, showed that
people at high risk for type 2 diabetes
could sharply lower their chances of
developing the disease through diet and
exercise. In addition, treatment with the
oral diabetes drug metformin also reduced
diabetes risk, though less dramatically.
Participants randomly assigned to
intensive lifestyle intervention reduced
their risk of getting type 2 diabetes by
58 percent. On average, this group
maintained their physical activity at 30
minutes per day, usually with walking or
other moderate intensity exercise, and
lost 5 to 7 percent of their body weight.
Participants randomized to treatment with
metformin reduced their risk of getting
type 2 diabetes by 31 percent.
Of the 3,234 participants enrolled in the
DPP, 45 percent were from minority groups
that suffer disproportionately from type 2
diabetes: African Americans, Hispanic
Americans, Asian Americans and Pacific
Islanders, and American Indians. The trial
also recruited other groups known to be at
higher risk for type 2 diabetes, including
individuals age 60 and older, women with a
history of gestational diabetes, and
people with a first-degree relative with
type 2 diabetes.
Several new drugs have been developed to
treat type 2 diabetes. By using the oral
diabetes medications now available, many
people can control blood glucose levels
without insulin injections. Studies are
under way to determine how best to use
these drugs to manage type 2 diabetes.
Scientists also are investigating
strategies for weight loss in people with
type 2 diabetes.
Points to Remember What is diabetes?
• a disorder of metabolism--the way the
body digests food for energy and growth
What are the main types of diabetes?
• type 1 diabetes
• type 2 diabetes
• gestational diabetes
What is the impact of diabetes?
• affects 17 million people
• is a leading cause of death and
disability
• costs $132 billion per year
Who gets diabetes?
• people of any age
• people with a family history of diabetes
• most common in older people, overweight
and sedentary people, African Americans,
Alaska Natives, American Indians, Asian
and Pacific Islander Americans, and
Hispanic Americans
Where Is More Information Available? For
more information about type 1, type 2, and
gestational diabetes, as well as diabetes
research, statistics, and education,
contact
National Diabetes Information
Clearinghouse
1 Information Way
Bethesda, MD 20892-3560
Phone: 1-800-860-8747 or (301) 654-3327
Email:
ndic
@info.niddk.nih.gov
The following organizations also
distribute materials and support programs
for people with diabetes and their
families and friends:
American Diabetes Association
National Service Center
1701 North Beauregard Street
Alexandria, VA 22311
Phone: 1-800-342-2383 or (703) 549-1500
Internet:
www.diabetes.org
Juvenile Diabetes Research Foundation
International
120 Wall Street, 19th Floor
New York, NY 10005
Phone: 1-800-533-2873 or (212) 785-9500
Internet:
www.jdrf.org
National Diabetes Information
Clearinghouse
1 Information Way
Bethesda, MD 20892-3560
Email:
ndic
@info.niddk.nih.gov
The National Diabetes Information
Clearinghouse (NDIC) is a service of the
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK). The
NIDDK is part of the National Institutes
of Health under the U.S. Department of
Health and Human Services. Established in
1978, the clearinghouse provides
information about diabetes to people with
diabetes and to their families, health
care professionals, and the public. NDIC
answers inquiries, develops and
distributes publications, and works
closely with professional and patient
organizations and Government agencies to
coordinate resources about diabetes.
Publications produced by the clearinghouse
are carefully reviewed by both NIDDK
scientists and outside experts.